26 January 2023 | 16:00-16:45 CET
About this webinar
Relapsing-remitting. Primary Progressive. Secondary Progressive. These are the primary descriptions used to define the various stages of multiple sclerosis. But what would happen if we moved away from such purely clinical descriptions, creating instead a new system based on underlying biology, rather than how the disease appears clinically?
In this ECTRIMS NeuroWebinar, an international panel of experts discuss their newly proposed “mechanism-driven” framework recently published in Lancet Neurology. The framework – developed under the auspices of the International Advisory Committee on Clinical Trials in MS, a group jointly sponsored by ECTRIMS and the US National MS Society – aims to better describe the disease course across the lifespan and lays the future groundwork for more personalised treatment options for people with MS.
Speaker: Alan J. Thompson, Dean of the Faculty of Brain Sciences at University College London, UK; editor of the Multiple Sclerosis Journal
Speaker: Tanja Kuhlmann, Associate Professor for Neuropathology in the Institute of Neuropathology at University Hospital Münster, Germany
Speaker: Daniel Reich, Senior Investigator in the Translational Neuroradiology Section of the National Institute of Health, UK
Moderator: Thomas Berger, Chair of the European Academy of Neurology (EAN) Scientific Committee, EAN Board Member and Professor of Neurology at MedUni Innsbruck.
This webinar is organised together with MS National Society and the European Academy of Neurology.